The transient receptor potential vanilloid 1 receptor (TRPV1) is a calcium-sensitive membrane receptor activated by capsaicin and the endocannabinoid, anandamide (AEA). Once activated in vitro, endometrial cancer (EC) cell growth appears to be inhibited through increased apoptosis, but the mechanism remains unclear. Our aim was to investigate the expression and distribution of TRPV1 in normal and cancerous endometria and to determine the precise in vitro mechanism of decreased EC cellular growth. TRPV1 expression in patients with endometrial carcinoma (15 Type 1 EC, six Type 2 EC) and six normal patients (atrophic endometria) was assessed using quantitative RT-PCR and immunohistochemistry (IHC). Additionally, immunohistochemical staining for the proliferation marker Ki-67, the pro-apoptotic marker BAX and the anti-apoptotic marker Bcl-2 were explored. TRPV1 transcript (p = 0.0054) and immunoreactive protein (p < 0.0001) levels were significantly reduced in all EC tissues when compared to control (atrophic) endometria. The almost 50% reduction in TRPV1 transcript levels was mirrored by an almost complete loss of immunoreactive TRPV1 protein. The increased proliferation (Ki-67) of EC tissues correlated with the expression of mutated BAX and inversely correlated to Bcl-2, but only in Type 2 EC samples. In vitro, AEA caused a decrease in Ishikawa cell numbers, whilst capsaicin did not, suggesting the anti-proliferative effect of AEA in EC cells is not via the TRPV1 receptor. In conclusion, the loss of TRPV1 expression in vivo plays a role in the aetiopathogenesis of EC. Activation of cells by AEA also probably promotes EC cell loss through a pro-apoptotic mechanism not involving TRPV1.

Keywords

anandamide; apoptosis; cell growth; endocannabinoid; endometrial cancer; vanilloid receptor.

1. Holman, L. L., & Lu, K. H. (2012). The epidemiology of endometrial cancer. Global Library of Women's Medicine, 41, 1–16.
2. American Cancer Society. (2018). Global cancer facts & figures. American Cancer Society.
3. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17–48.
4. Sheikh, M. A., Althouse, A. D., Freese, K. E., Soisson, S., Edwards, R. P., Welburn, S., Sukumvanich, P., Comerci, J., Kelley, J., LaPorte, R. E., Linkov, F., & Krivak, T. C. (2014). USA endometrial cancer projections to 2030: Should we be concerned? Future Oncology, 10(16), 2561–2568.
5. Evans, T., Sany, O., Pearmain, P., Ganesan, R., Blann, A., & Sundar, S. (2011). Differential trends in the rising incidence of endometrial cancer by type: Data from a UK population-based registry from 1994 to 2006. British Journal of Cancer, 104(9), 1505–1510.
6. Yasin, H. K., Taylor, A. H., & Ayakannu, T. (2021). A narrative review of the role of diet and lifestyle factors in the development and prevention of endometrial cancer. Cancers, 13(9), Article 2149.
7. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090), 1946–1949.
8. Ayakannu, T., Taylor, A. H., Bari, M., Mastrangelo, N., Maccarrone, M., & Konje, J. C. (2019). Expression and function of the endocannabinoid modulating enzymes fatty acid amide hydrolase and N-acylphosphatidylethanolamine-specific phospholipase D in endometrial carcinoma. Frontiers in Oncology, 9, Article 1363.
9. Ayakannu, T., Taylor, A. H., Marczylo, T. H., Willets, J. M., & Konje, J. C. (2013). The endocannabinoid system and sex steroid hormone-dependent cancers. International Journal of Endocrinology, 2013, Article 259676.
10. Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365(6441), 61–65.
11. Sawzdargo, M., Nguyen, T., Lee, D. K., Lynch, K. R., Cheng, R., Heng, H. H., George, S. R., & O’Dowd, B. F. (1999). Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Molecular Brain Research, 64(2), 193–198.
12. Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997). The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature, 389(6653), 816–824.
13. Ayakannu, T., Taylor, A. H., & Konje, J. C. (2018). Cannabinoid receptor expression in estrogen-dependent and estrogen-independent endometrial cancer. Journal of Receptors and Signal Transduction, 38(5–6), 385–392.
14. Ayakannu, T., Taylor, A. H., Marczylo, T. H., Maccarrone, M., & Konje, J. C. (2019). Identification of novel predictive biomarkers for endometrial malignancies: N-acylethanolamines. Frontiers in Oncology, 9, Article 430.
15. Risinger, J. I., Maxwell, G. L., Chandramouli, G. V., Jazaeri, A., Aprelikova, O., Patterson, T., Berchuck, A., & Barrett, J. C. (2003). Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Research, 63(1), 6–11.
16. Fonseca, B. M., Correia-da-Silva, G., & Teixeira, N. A. (2018). Cannabinoid-induced cell death in endometrial cancer cells: Involvement of TRPV1 receptors in apoptosis. Journal of Physiology and Biochemistry, 74(2), 261–272.
17. Guida, M., Ligresti, A., De Filippis, D., D’Amico, A., Petrosino, S., Cipriano, M., Bifulco, G., Simonetti, S., Orlando, P., Insabato, L., Iuvone, T., & Di Marzo, V. (2010). The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. Endocrinology, 151(3), 921–928.
18. Brown, A. J. (2007). Novel cannabinoid receptors. British Journal of Pharmacology, 152(5), 567–575.
19. Wilkinson, J. D., & Williamson, E. M. (2007). Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. Journal of Dermatological Science, 45(2), 87–92.
20. Ayakannu, T., Taylor, A. H., Willets, J. M., Brown, L., Lambert, D. G., McDonald, J., Davies, Q., Moss, E. L., & Konje, J. C. (2015). Validation of endogenous control reference genes for normalizing gene expression studies in endometrial carcinoma. Molecular Human Reproduction, 21(9), 723–735.
21. Taylor, A. H., Tortolani, D., Ayakannu, T., Konje, J. C., & Maccarrone, M. (2020). (Endo)cannabinoids and gynaecological cancers. Cancers, 13(1), Article 37.
22. Hu, G., Ren, G., & Shi, Y. (2011). The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. Oncogene, 30(2), 139–141.
23. Andradas, C., Caffarel, M. M., Perez-Gomez, E., Salazar, M., Lorente, M., Velasco, G., Guzman, M., & Sanchez, C. (2011). The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene, 30(2), 245–252.
24. Pineiro, R., Maffucci, T., & Falasca, M. (2011). The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene, 30(2), 142–152.
25. Kalogris, C., Caprodossi, S., Amantini, C., Lambertucci, F., Nabissi, M., Morelli, M. B., Farfariello, V., Filosa, A., Emiliozzi, M. C., Mammana, G., & Santoni, G. (2010). Expression of transient receptor potential vanilloid-1 (TRPV1) in urothelial cancers of human bladder: Relation to clinicopathological and molecular parameters. Histopathology, 57(5), 744–752.
26. Domotor, A., Peidl, Z., Vincze, A., Hunyady, B., Szolcsanyi, J., Kereskay, L., Szekeres, G., & Mozsik, G. (2005). Immunohistochemical distribution of vanilloid receptor, calcitonin-gene related peptide and substance P in gastrointestinal mucosa of patients with different gastrointestinal disorders. Inflammopharmacology, 13(1–3), 161–177.
27. Hartel, M., di Mola, F. F., Selvaggi, F., Mascetta, G., Wente, M. N., Felix, K., Giese, N. A., Hinz, U., Di Sebastiano, P., Buchler, M. W., & Friess, H. (2006). Vanilloids in pancreatic cancer: Potential for chemotherapy and pain management. Gut, 55(4), 519–528.
28. Ayakannu, T., Taylor, A. H., & Konje, J. C. (2021). Expression of the putative cannabinoid receptor GPR55 is increased in endometrial carcinoma. Histochemistry and Cell Biology, 156(5), 449–460.
29. Mutch, D. G. (2009). The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecologic Oncology, 115(3), 325–328.
30. Marincsák, R., Tóth, B., Czifra, G., Márton, I., Rédl, P., Tar, I., Tóth, L., Kovács, L., & Bíró, T. (2009). Increased expression of TRPV1 in squamous cell carcinoma of the human tongue. Oral Diseases, 15(5), 328–335.
31. Czifra, G., Varga, A., Nyeste, K., Marincsák, R., Tóth, B. I., Kovács, I., Kovács, L., & Bíró, T. (2009). Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. Journal of Cancer Research and Clinical Oncology, 135(4), 507–514.
32. Ayakannu, T., Taylor, A. H., Marczylo, T. H., & Konje, J. C. (2019). New insights of uterine leiomyoma pathogenesis: Endocannabinoid system. Medical Science Monitor Basic Research, 25, 76–87.
33. Mistretta, F., Buffi, N. M., Lughezzani, G., Lista, G., Larcher, A., Fossati, N., Abrate, A., Dell’Oglio, P., Montorsi, F., Guazzoni, G., & Lazzeri, M. (2014). Bladder cancer and urothelial impairment: The role of TRPV1 as potential drug target. BioMed Research International, 2014, Article 987149.
34. Lozano, C., Cordova, C., Marchant, I., Zuniga, R., Ochova, P., Ramirez-Barrantes, R., Gonzalez-Arriagada, W. A., Rodriguez, B., & Olivero, P. (2018). Intracellular aggregated TRPV1 is associated with lower survival in breast cancer patients. Breast Cancer: Targets and Therapy, 10, 161–168.
35. Li, L., Chen, C., Chiang, C., Xiao, T., Chen, Y., Zhao, Y., & Zheng, D. (2021). The impact of TRPV1 on cancer pathogenesis and therapy: A systematic review. International Journal of Biological Sciences, 17(8), 2034–2049.
36. Han, G. H., Chay, D. B., Nam, S., Cho, H., Chung, J. Y., & Kim, J. H. (2020). Prognostic significance of transient receptor potential vanilloid type 1 (TRPV1) and phosphatase and tension homolog (PTEN) in epithelial ovarian cancer. Cancer Genomics & Proteomics, 17(3), 309–319.
37. Culjkovic-Kraljacic, B., & Borden, K. L. B. (2018). The impact of post-transcriptional control: Better living through RNA regulons. Frontiers in Genetics, 9, Article 512.
38. McKallip, R. J., Nagarkatti, M., & Nagarkatti, P. S. (2005). Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. The Journal of Immunology, 174(6), 3281–3289.
39. Wang, D., Wang, H., Ning, W., Backlund, M. G., Dey, S. K., & DuBois, R. N. (2008). Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Research, 68(16), 6468–6476.
40. Cudaback, E., Marrs, W., Moeller, T., & Stella, N. (2010). The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PLoS ONE, 5(1), Article e8702.
41. Gustafsson, K., Wang, X., Severa, D., Eriksson, M., Kimby, E., Merup, M., Christensson, B., Flygare, J., & Sander, B. (2008). Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by receptor activation. International Journal of Cancer, 123(5), 1025–1033.
42. Chung, S. C., Hammarsten, P., Josefsson, A., Stattin, P., Granfors, T., Egevad, L., Mancini, G., Lutz, B., Bergh, A., & Fowler, C. J. (2009). A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. European Journal of Cancer, 45(1), 174–182.
43. Michalski, C. W., Oti, F. E., Erkan, M., Sauliunaite, D., Bergmann, F., Pacher, P., Batkai, S., Müller, M. W., Giese, N. A., Friess, H., & Kleeff, J. (2008). Cannabinoids in pancreatic cancer: Correlation with survival and pain. International Journal of Cancer, 122(4), 742–750.
44. Gustafsson, S. B., Lindgren, T., Jonsson, M., & Jacobsson, S. O. P. (2009). Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: Synergism with 5-fluorouracil. Cancer Chemotherapy and Pharmacology, 63(4), 691–701.
45. Ligresti, A., De Petrocellis, L., Hernán Pérez de la Ossa, D., Aberturas, R., Cristino, L., Moriello, A. S., Finizio, A., Gil, M. E., Torres, A. I., Molpeceres, J., & Di Marzo, V. (2010). Exploiting nanotechnologies and TRPV1 channels to investigate the putative anandamide membrane transporter. PLoS ONE, 5(4), Article e10239.
46. Wong, G. Y., & Gavva, N. R. (2009). Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. Brain Research Reviews, 60(1), 267–277.
47. Hanson, S. M., Newstead, S., Swartz, K. J., & Sansom, M. S. (2015). Capsaicin interaction with TRPV1 channels in a lipid bilayer: Molecular dynamics simulation. Biophysical Journal, 108(6), 1425–1434.
48. Devor, E. J., Gonzalez-Bosquet, J., Thiel, K. W., & Leslie, K. K. (2020). Genomic characterization of five commonly used endometrial cancer cell lines. International Journal of Oncology, 57(6), 1348–1357.
49. Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004). Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science, 303(5660), 1010–1014.
50. Muller, C., Lynch, D. L., Hurst, D. P., & Reggio, P. H. (2020). A closer look at anandamide interaction with TRPV1. Frontiers in Molecular Biosciences, 7, Article 144.
51. Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., & Darai, E. (2016). Endometrial cancer. The Lancet, 387(10023), 1094–1108.
52. Zhao, G., Zhu, Y., Eno, C. O., Liu, Y., Deleeuw, L., Burlison, J. A., Chaires, J. B., Trent, J. O., & Li, C. (2014). Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis. Molecular and Cellular Biology, 34(7), 1198–1207.
53. Vandenabeele, P., Bultynck, G., & Savvides, S. N. (2023). Pore-forming proteins as drivers of membrane permeabilization in cell death pathways. Nature Reviews Molecular Cell Biology, 24(5), 312–333.
54. Wang, K., Gross, A., Waksman, G., & Korsmeyer, S. J. (1998). Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing. Molecular and Cellular Biology, 18(10), 6083–6089.
55. Hao, Q., Chen, J., Lu, H., & Zhou, X. (2023). The ARTS of p53-dependent mitochondrial apoptosis. Journal of Molecular Cell Biology, 14(12), Article mjac074.
56. Levine, A. J. (1997). p53, the cellular gatekeeper for growth and division. Cell, 88(3), 323–331.
57. Menendez-Perez, C., Rivas-Santisteban, R., Del Valle, E., Tolivia, J., Navarro, A., Franco, R., & Martinez-Pinilla, E. (2024). Heteromers formed by GPR55 and either cannabinoid CB(1) or CB(2) receptors are upregulated in the prefrontal cortex of multiple sclerosis patients. International Journal of Molecular Sciences, 25(8), Article 4176.
58. Kashyap, D., Garg, V. K., & Goel, N. (2021). Intrin